Czechia hopes for Novavax vaccine approval

The European Medicines Agency (EMA) started evaluating an application to authorise the Novavax vaccine in mid-November 2021. [Shutterstock / vovidzha]

Swift approval of the Novavax COVID-19 vaccine is being eyed by Czechia, as the country hopes this will convince the unvaccinated to take the jab.

According to the government, protein-based vaccines such as Novavax could convince unvaccinated people to change their minds, as the currently used mRNA vaccines are often targets of massive disinformation campaigns.

“This vaccine could become an alternative for those people who are for some reason – even if the reason is based on disinformation – not willing to be vaccinated with already available vaccines,” said Czech Health Minister Adam Vojtěch.

The European Medicines Agency (EMA) started evaluating an application to authorise the Novavax vaccine in mid-November 2021. Moreover, Novavax is nearing approval from the US authorities soon.

Czechia has ordered 370.000 doses of the Novavax vaccine. The health ministry expects deliveries of protein-based vaccines at the beginning of 2022. A key component of the candidate vaccine will be produced by Novavax’s manufacturing facility located nearby Prague.

EMA has already authorised Pfizer and Moderna vaccines that use mRNA to produce an immune response to the virus spike protein, and AstraZeneca and Johnson & Johnson that are made up of another virus.

Novavax is currently the only vaccine producer in the final stage of EMA authorisation as it has submitted a marketing authorisation application. Valneva and Sanofi, other prominent vaccines against COVID-19, are still under rolling review, thus lagging behind Novavax.

(Aneta Zachová | EURACTIV.cz)

Subscribe to our newsletters

Subscribe